STRUCTURE PEPTIDE/CONSERVED T CELL RECEPTOR DETERMINING DIABETES
决定糖尿病的结构肽/保守 T 细胞受体
基本信息
- 批准号:8052888
- 负责人:
- 金额:$ 24.65万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-04-01 至 2013-03-31
- 项目状态:已结题
- 来源:
- 关键词:Amino AcidsAntigensAutoantibodiesAutoantigensAutoimmunityB-insulinC57BL/6 MouseCellsConserved SequenceCritical PathwaysDataDevelopmentDiabetes MellitusDiseaseFutureGerm LinesGoalsHumanImmuneImmunotherapyInbred NOD MiceInfiltrationInsulinInsulin-Dependent Diabetes MellitusIslets of LangerhansKnock-in MouseKnock-outLocationMethodologyModelingMolecularMusPancreasPathway interactionsPeptidesPhasePreventionSequence DeletionSpecificitySpeedStagingSystemT-Cell ReceptorT-Cell Receptors alpha-ChainT-LymphocyteTechniquesTestingTimeTransplantationbaseclinically relevantcongenicdiabetic patientdisorder preventionendocrine pancreas developmentgenome sequencingisletlaser capture microdissectionmanmouse developmentmouse modelnovelpeptide Bpeptide structurepreventreconstitutionrestoration
项目摘要
Our data indicates that insulin B chain amino acids 9 to 23 peptide (insulin B:9-23) may be a primary target
essential for the initiation of spontaneous diabetes in NOD mice and that T cells recognizing this peptide
have a T cell receptor that specifically shares conserved Valpha and Jalpha segments. I will define using
transplants, the specific timing and location of the contribution of insulin B:9-23 in the development of islet
autoimmunity. I will also directly test the hypothesis that genomically encoded T cell receptor chains are
crucial for disease in the NOD mouse and for recognition by the T cell repertoire of the insulin B:9-23
peptide. I propose to create NOD mice having the presumed "irrelevant" single Jalpha 56 segment, which
has different sequence from the conserved Jalpha segment (53/42), and to evaluate them for development
of anti-islet autoimmunity. C57BL/6 mice bearing only Jalpha 56 were established where a single Jalpha is
used to create the immune repertoire, and we will create congenic Jalpha 56 NOD mice using speed
congenic techniques. I predict if the Jalpha 53/42 conserved sequences are critical, anti-insulin/islet
autoimmunity will not develop for NOD mice having only the "irrelevant" Jalpha 56 sequence. If prevention
occurs in mice with the single Jalpha 56, we will molecularly create mice with the single Jalpha 56 sequence
modified to be a Jalpha 53 sequence, and I predict restoration of autoimmunity. For the independent phase, I
will define sequences of the conserved alpha chain that confer anti-insulin autoimmunity with novel
molecular retrogenic techniques. Producing retrogenic mice with the original and modified alpha chain T cell
receptors will allow us to define crucial sequences. We will molecularly transfer amino acid cassettes from
the conserved Valpha and Jalpha of anti-B:9-23 diabetogenic clones into a "irrelevant" control alpha chain to
assess whether we can create anti-insulin autoimmunity, and will transfer amino acid cassettes from control
alpha chain into anti-B:9-23 diabetogenic alpha chains to suppress or abrogate autoimmunity. If this
pathway is critical in the NOD mouse, it will stimulate a search for an analogous human critical pathway. As
a long-term goal, plans are included to first develop methodology in the mouse model and eventually apply
similar retrogenic and molecular techniques to T cell receptors of man from pancreatic islet infiltration of
man.
我们的数据表明,胰岛素B链氨基酸9-23肽(胰岛素B:9-23)可能是主要的靶标
NOD小鼠自发性糖尿病的发生和识别该肽的T细胞
有一个T细胞受体,专门分享保守的Valpha和Jpha片段。我将使用以下内容定义
移植,胰岛素B:9-23在胰岛发育中作用的具体时间和位置
自身免疫力。我还将直接测试这样一个假设,即基因编码的T细胞受体链是
对NOD小鼠的疾病和T细胞识别胰岛素B:9-23至关重要
多肽。我建议创造NOD小鼠,该小鼠具有推定的“无关”的单个Jalpha56片段,该片段
具有与保守的Jpha片段(53/42)不同的序列,并对它们进行发育评估
抗胰岛自身免疫力。只携带Jalpha56的C57BL/6小鼠被建立在只有一个Jpha56的C57BL/6小鼠
用来创建免疫系统,我们将使用SPEED创建同源的Jalpha56nod小鼠
同源基因技术。我预测Jalpha53/42保守序列是否是关键的抗胰岛素/胰岛
仅有Jalpha56“无关”序列的NOD小鼠不会产生自身免疫。如果预防
发生在具有单个Jalpha56序列的小鼠中,我们将从分子上创建具有单个Jalpha56序列的小鼠
被修改为Jalpha53序列,我预测自身免疫功能恢复。对于独立阶段,我
将定义保守的阿尔法链序列,使抗胰岛素自身免疫具有新的
分子回溯技术。用原始和修饰的阿尔法链T细胞制备逆转录基因小鼠
受体将允许我们定义关键序列。我们将从分子上转移氨基酸盒
抗-B:9-23致糖尿病克隆的保守的Valpha和Jpha进入一个“无关”的控制阿尔法链
评估我们是否可以创造抗胰岛素自身免疫,并将从控制组转移氨基酸盒
α链进入抗B:9-23致糖尿病的阿尔法链,以抑制或消除自身免疫。如果这个
途径在NOD小鼠中是关键的,它将刺激人们寻找类似人类的关键途径。AS
作为一个长期目标,计划首先在小鼠模型中开发方法学并最终应用
类似逆转录和分子生物学技术的人T细胞受体从胰岛浸润性
天哪。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Maki Nakayama其他文献
Maki Nakayama的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Maki Nakayama', 18)}}的其他基金
The Antigen Repertoire of CD4 T cells from Pancreatic Islets
胰岛 CD4 T 细胞的抗原库
- 批准号:
10503562 - 财政年份:2022
- 资助金额:
$ 24.65万 - 项目类别:
The Antigen Repertoire of CD4 T cells from Pancreatic Islets
胰岛 CD4 T 细胞的抗原库
- 批准号:
10700133 - 财政年份:2022
- 资助金额:
$ 24.65万 - 项目类别:
Molecular Dissection of Insulin Targeting in Anti-Islet Autoimmunity
抗胰岛自身免疫中胰岛素靶向的分子解析
- 批准号:
9302736 - 财政年份:2013
- 资助金额:
$ 24.65万 - 项目类别:
Molecular Dissection of Insulin Targeting in Anti-Islet Autoimmunity
抗胰岛自身免疫中胰岛素靶向的分子解析
- 批准号:
8883519 - 财政年份:2013
- 资助金额:
$ 24.65万 - 项目类别:
Molecular Dissection of Insulin Targeting in Anti-Islet Autoimmunity
胰岛素靶向抗胰岛自身免疫的分子解析
- 批准号:
9104151 - 财政年份:2013
- 资助金额:
$ 24.65万 - 项目类别:
Molecular Dissection of Insulin Targeting in Anti-Islet Autoimmunity
胰岛素靶向抗胰岛自身免疫的分子解析
- 批准号:
8562380 - 财政年份:2013
- 资助金额:
$ 24.65万 - 项目类别:
Molecular Dissection of Insulin Targeting in Anti-Islet Autoimmunity
胰岛素靶向抗胰岛自身免疫的分子解析
- 批准号:
8723188 - 财政年份:2013
- 资助金额:
$ 24.65万 - 项目类别:
STRUCTURE PEPTIDE/CONSERVED T CELL RECEPTOR DETERMINING DIABETES
决定糖尿病的结构肽/保守 T 细胞受体
- 批准号:
8009618 - 财政年份:2010
- 资助金额:
$ 24.65万 - 项目类别:
相似国自然基金
Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
- 批准号:2022J011295
- 批准年份:2022
- 资助金额:10.0 万元
- 项目类别:省市级项目
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究
- 批准号:30801055
- 批准年份:2008
- 资助金额:19.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Autoantibodies directed to islet cell surface antigens and their pathologic roles in type-1 diabetes
针对胰岛细胞表面抗原的自身抗体及其在 1 型糖尿病中的病理作用
- 批准号:
10161015 - 财政年份:2020
- 资助金额:
$ 24.65万 - 项目类别:
Investigation of the autoantibodies against complex antigens formed by two lipid molecules in neuroimmunological diseases
神经免疫疾病中两种脂质分子形成的复合抗原自身抗体的研究
- 批准号:
18H02745 - 财政年份:2018
- 资助金额:
$ 24.65万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Autoantibodies to tumor-associated antigens as diagnostic biomarkers in liver can
肿瘤相关抗原的自身抗体作为肝脏的诊断生物标志物可以
- 批准号:
8509638 - 财政年份:2011
- 资助金额:
$ 24.65万 - 项目类别:
Autoantibodies to tumor-associated antigens as diagnostic biomarkers in liver can
肿瘤相关抗原的自身抗体作为肝脏的诊断生物标志物可以
- 批准号:
8704893 - 财政年份:2011
- 资助金额:
$ 24.65万 - 项目类别:
Autoantibodies to tumor-associated antigens as diagnostic biomarkers in liver can
肿瘤相关抗原的自身抗体作为肝脏的诊断生物标志物可以
- 批准号:
8313868 - 财政年份:2011
- 资助金额:
$ 24.65万 - 项目类别:
Autoantibodies to tumor-associated antigens as diagnostic biomarkers in liver can
肿瘤相关抗原的自身抗体作为肝脏的诊断生物标志物可以
- 批准号:
8150727 - 财政年份:2011
- 资助金额:
$ 24.65万 - 项目类别:
Follicular Exclusion of Self Antigens Prevents Development of Autoantibodies
滤泡排除自身抗原可防止自身抗体的产生
- 批准号:
8795154 - 财政年份:2008
- 资助金额:
$ 24.65万 - 项目类别:
Follicular Exclusion of Self Antigens Prevents Development of Autoantibodies
滤泡排除自身抗原可防止自身抗体的产生
- 批准号:
8695576 - 财政年份:2008
- 资助金额:
$ 24.65万 - 项目类别:
Follicular Exclusion of Self Antigens Prevents Development of Autoantibodies
滤泡排除自身抗原可防止自身抗体的产生
- 批准号:
9208730 - 财政年份:2008
- 资助金额:
$ 24.65万 - 项目类别:
Identifications of non-Hodgkin's lymphoma (NHL)-specific antigens bounded with autoantibodies in plasma derived from patients with NHL by an autoantibodiomics
通过自身抗体组学鉴定 NHL 患者血浆中与自身抗体结合的非霍奇金淋巴瘤 (NHL) 特异性抗原
- 批准号:
19590574 - 财政年份:2007
- 资助金额:
$ 24.65万 - 项目类别:
Grant-in-Aid for Scientific Research (C)














{{item.name}}会员




